262 related articles for article (PubMed ID: 35902132)
1. Reshaping the tumor microenvironment with oncolytic viruses, positive regulation of the immune synapse, and blockade of the immunosuppressive oncometabolic circuitry.
Nguyen TT; Shin DH; Sohoni S; Singh SK; Rivera-Molina Y; Jiang H; Fan X; Gumin J; Lang FF; Alvarez-Breckenridge C; Godoy-Vitorino F; Zhu L; Zheng WJ; Zhai L; Ladomersky E; Lauing KL; Alonso MM; Wainwright DA; Gomez-Manzano C; Fueyo J
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35902132
[TBL] [Abstract][Full Text] [Related]
2. Blockade of IDO-Kynurenine-AhR Axis Ameliorated Colitis-Associated Colon Cancer via Inhibiting Immune Tolerance.
Zhang X; Liu X; Zhou W; Du Q; Yang M; Ding Y; Hu R
Cell Mol Gastroenterol Hepatol; 2021; 12(4):1179-1199. PubMed ID: 34087454
[TBL] [Abstract][Full Text] [Related]
3. Blockade of the AHR restricts a Treg-macrophage suppressive axis induced by L-Kynurenine.
Campesato LF; Budhu S; Tchaicha J; Weng CH; Gigoux M; Cohen IJ; Redmond D; Mangarin L; Pourpe S; Liu C; Zappasodi R; Zamarin D; Cavanaugh J; Castro AC; Manfredi MG; McGovern K; Merghoub T; Wolchok JD
Nat Commun; 2020 Aug; 11(1):4011. PubMed ID: 32782249
[TBL] [Abstract][Full Text] [Related]
4. Reimagining IDO Pathway Inhibition in Cancer Immunotherapy via Downstream Focus on the Tryptophan-Kynurenine-Aryl Hydrocarbon Axis.
Labadie BW; Bao R; Luke JJ
Clin Cancer Res; 2019 Mar; 25(5):1462-1471. PubMed ID: 30377198
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic Adenovirus and Tumor-Targeting Immune Modulatory Therapy Improve Autologous Cancer Vaccination.
Jiang H; Rivera-Molina Y; Gomez-Manzano C; Clise-Dwyer K; Bover L; Vence LM; Yuan Y; Lang FF; Toniatti C; Hossain MB; Fueyo J
Cancer Res; 2017 Jul; 77(14):3894-3907. PubMed ID: 28566332
[TBL] [Abstract][Full Text] [Related]
6. Indoleamine 2,3-Dioxygenase Activity-Induced Acceleration of Tumor Growth, and Protein Kinases-Related Novel Therapeutics Regimens.
Engin AB; Engin A
Adv Exp Med Biol; 2021; 1275():339-356. PubMed ID: 33539022
[TBL] [Abstract][Full Text] [Related]
7. Indoleamine 2, 3-Dioxygenase Promotes Aryl Hydrocarbon Receptor-Dependent Differentiation Of Regulatory B Cells in Lung Cancer.
Tousif S; Wang Y; Jackson J; Hough KP; Strenkowski JG; Athar M; Thannickal VJ; McCusker RH; Ponnazhagan S; Deshane JS
Front Immunol; 2021; 12():747780. PubMed ID: 34867973
[TBL] [Abstract][Full Text] [Related]
8. Targeting the aryl hydrocarbon receptor (AhR) with BAY 2416964: a selective small molecule inhibitor for cancer immunotherapy.
Kober C; Roewe J; Schmees N; Roese L; Roehn U; Bader B; Stoeckigt D; Prinz F; Gorjánácz M; Roider HG; Olesch C; Leder G; Irlbacher H; Lesche R; Lefranc J; Oezcan-Wahlbrink M; Batra AS; Elmadany N; Carretero R; Sahm K; Oezen I; Cichon F; Baumann D; Sadik A; Opitz CA; Weinmann H; Hartung IV; Kreft B; Offringa R; Platten M; Gutcher I
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 37963637
[TBL] [Abstract][Full Text] [Related]
9. Carboxyamidotriazole combined with IDO1-Kyn-AhR pathway inhibitors profoundly enhances cancer immunotherapy.
Shi J; Chen C; Ju R; Wang Q; Li J; Guo L; Ye C; Zhang D
J Immunother Cancer; 2019 Sep; 7(1):246. PubMed ID: 31511064
[TBL] [Abstract][Full Text] [Related]
10. PCC0208009 enhances the anti-tumor effects of temozolomide through direct inhibition and transcriptional regulation of indoleamine 2,3-dioxygenase in glioma models.
Sun S; Du G; Xue J; Ma J; Ge M; Wang H; Tian J
Int J Immunopathol Pharmacol; 2018; 32():2058738418787991. PubMed ID: 29993291
[TBL] [Abstract][Full Text] [Related]
11. Investigating the Role of Indoleamine 2,3-Dioxygenase in Acute Myeloid Leukemia: A Systematic Review.
Wells G; Kennedy PT; Dahal LN
Front Immunol; 2021; 12():651687. PubMed ID: 33777052
[No Abstract] [Full Text] [Related]
12. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
Schafer CC; Wang Y; Hough KP; Sawant A; Grant SC; Thannickal VJ; Zmijewski J; Ponnazhagan S; Deshane JS
Oncotarget; 2016 Nov; 7(46):75407-75424. PubMed ID: 27705910
[TBL] [Abstract][Full Text] [Related]
13. Canine mast cell tumour cells regulate tryptophan catabolism via the expression of indoleamine 2,3-dioxygenase.
Matsuda A; Hata A; Tanaka A; Matsuda H
Res Vet Sci; 2021 Jul; 137():159-162. PubMed ID: 33984619
[TBL] [Abstract][Full Text] [Related]
14. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
[TBL] [Abstract][Full Text] [Related]
15. IDO/kynurenine pathway in cancer: possible therapeutic approaches.
Abd El-Fattah EE
J Transl Med; 2022 Aug; 20(1):347. PubMed ID: 35918736
[TBL] [Abstract][Full Text] [Related]
16. Immune modulations during chemoimmunotherapy & novel vaccine strategies--in metastatic melanoma and non small-cell lung cancer.
Iversen TZ
Dan Med J; 2013 Dec; 60(12):B4774. PubMed ID: 24355457
[TBL] [Abstract][Full Text] [Related]
17. Deep learning model enables the discovery of a novel immunotherapeutic agent regulating the kynurenine pathway.
Kim JH; Lee WS; Lee HJ; Yang H; Lee SJ; Kong SJ; Je S; Yang HJ; Jung J; Cheon J; Kang B; Chon HJ; Kim C
Oncoimmunology; 2021; 10(1):2005280. PubMed ID: 34858729
[TBL] [Abstract][Full Text] [Related]
18. Indoleamine 2,3-dioxygenase (IDO) inhibitors and cancer immunotherapy.
Fujiwara Y; Kato S; Nesline MK; Conroy JM; DePietro P; Pabla S; Kurzrock R
Cancer Treat Rev; 2022 Nov; 110():102461. PubMed ID: 36058143
[TBL] [Abstract][Full Text] [Related]
19. Localized Treatment with Oncolytic Adenovirus Delta-24-RGDOX Induces Systemic Immunity against Disseminated Subcutaneous and Intracranial Melanomas.
Jiang H; Shin DH; Nguyen TT; Fueyo J; Fan X; Henry V; Carrillo CC; Yi Y; Alonso MM; Collier TL; Yuan Y; Lang FF; Gomez-Manzano C
Clin Cancer Res; 2019 Nov; 25(22):6801-6814. PubMed ID: 31455679
[TBL] [Abstract][Full Text] [Related]
20. Blocking Indolamine-2,3-Dioxygenase Rebound Immune Suppression Boosts Antitumor Effects of Radio-Immunotherapy in Murine Models and Spontaneous Canine Malignancies.
Monjazeb AM; Kent MS; Grossenbacher SK; Mall C; Zamora AE; Mirsoian A; Chen M; Kol A; Shiao SL; Reddy A; Perks JR; T N Culp W; Sparger EE; Canter RJ; Sckisel GD; Murphy WJ
Clin Cancer Res; 2016 Sep; 22(17):4328-40. PubMed ID: 26979392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]